A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer

被引：0

作者：

Church, David N. ^{[1
]}

Price, Chris G. A. ^{[2
]}

机构：

[1] Univ Oxford, John Racliffe Hosp, Weatherall Inst Mol Med, Headley Way, Oxford OX3 9DS, England

[2] Bristol Haematol & Oncol Ctr, Bristol BS1 8ED, Avon, England

来源：

CLINICAL MEDICINE INSIGHTS-THERAPEUTICS | 2009年 / 1卷

关键词：

breast cancer; trastuzumab; metastatic; ERBB2; HER2;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The ERBB2 or HER2 receptor is overexpressed in 25% of breast cancers and is associated with poor prognosis. Trastuzumab, a monoclonal antibody targeting HER2 has been demonstrated to improve survival when combined with chemotherapy for the treatment of HER2 overexpressing metastatic breast cancer (MBC). Further studies have endeavoured to clarify the optimum chemotherapy regimen in combination with trastuzumab for MBC and its use together with novel biological agents. This review summarises these data together with preclinical studies exploring the mechanism of trastuzumab action and causes of drug resistance. The frequent incidence of brain metastases in patients on trastuzumab is highlighted, and data on the continuation of trastuzumab following CNS and non-CNS progression reviewed.

引用

页码：557 / 570

页数：14

共 50 条

[31] Preoperative therapy with trastuzumab and oral vinorelbine (± endocrine therapy) in patients with HER2-positive breast cancer
Iorfida, Monica
Bagnardi, Vincenzo
Balduzzi, Alessandra
Dellapasqua, Silvia
Cardillo, Anna
Luini, Alberto
Intra, Mattia
Minchella, Ida
Veronesi, Paolo
Viale, Giuseppe
Goldhirsch, Aron
Colleoni, Marco
BREAST, 2010, 19 (02) : 128 - 132
[32] Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remission
Haq, R.
Gulasingam, P.
CURRENT ONCOLOGY, 2016, 23 (02) : 91 - 95
[33] Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
Acevedo-Gadea, Carlos
Hatzis, Christos
Chung, Gina
Fishbach, Neal
Lezon-Geyda, Kimberly
Zelterman, Daniel
DiGiovanna, Michael P.
Harris, Lyndsay
Abu-Khalaf, Maysa M.
BREAST CANCER RESEARCH AND TREATMENT, 2015, 150 (01) : 157 - 167
[34] Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer
Rupert Bartsch
Catharina De Vries
Ursula Pluschnig
Peter Dubsky
Zsuzsanna Bago-Horvath
Simon P Gampenrieder
Margaretha Rudas
Robert M Mader
Andrea Rottenfusser
Christoph Wiltschke
Michael Gnant
Christoph C Zielinski
Guenther G Steger
BMC Cancer, 9
[35] Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
R Y Tsang
R S Finn
British Journal of Cancer, 2012, 106 : 6 - 13
[36] Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
Carlos Acevedo-Gadea
Christos Hatzis
Gina Chung
Neal Fishbach
Kimberly Lezon-Geyda
Daniel Zelterman
Michael P. DiGiovanna
Lyndsay Harris
Maysa M. Abu-Khalaf
Breast Cancer Research and Treatment, 2015, 150 : 157 - 167
[37] Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
Tsang, R. Y.
Finn, R. S.
BRITISH JOURNAL OF CANCER, 2012, 106 (01) : 6 - 13
[38] Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique
Parkinson, Bonny
Pearson, Sallie-Anne
Viney, Rosalie
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 (01) : 93 - 112
[39] Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique
Bonny Parkinson
Sallie-Anne Pearson
Rosalie Viney
The European Journal of Health Economics, 2014, 15 : 93 - 112
[40] Overall Survival Benefit from Trastuzumab-Based Treatment in HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis
Lv, Shuzhen
Wang, Yunchao
Sun, Tao
Wan, Donggui
Sheng, Lijun
Li, Wei
Zhu, Huayun
Li, Yanping
Lu, Janice
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (7-8) : 450 - 455

← 1 2 3 4 5 →